Prolonged inhibition of class I PI3K promotes liver CSC expansion by augmenting SGK3-dependent β-catenin stabilisation, and effective inhibition of SGK3 signalling may be useful in eliminating liver CSCs and in PI3K pathway-targeted cancer therapies. The gene discussed is PIK3CA; the disease is cancer.